The probable long-term survival in patients with diffuse mixed, histiocytic or undifferentiated non-Burkitt's non-Hodgkins lymphoma can be predicted from clinical factors determined prior to initiation of therapy. This can help determine how aggressive the therapeutic regimen should be.
Except for male gender, these factors affected the likelihood of complete remission. If a complete remission was obtained following therapy, then patient survival was improved.
Parameter
Adverse Indicator
sex
male
symptoms
at least one of the B symptoms present
bone marrow involvement
present
intra-abdominal disease
huge abdominal masses (> 10 cm) with gastrointestinal involvement
Additional factors with some negative impact:
(1) advanced stage (Ann Arbor stage III or IV)
(2) hepatic involvement
(3) hemoglobin < 12 g/dL
(4) serum LDH > 250 U/L
To read more or access our algorithms and calculators, please log in or register.
